Urotensin II (UII) is a cyclic peptide that holds the distinction of being the most potent vasoconstrictor peptide identified in mammals — approximately 10-fold more potent than endothelin-1 in certain vascular beds. Originally isolated from the urophysis of the goby fish (Gillichthys mirabilis) by Karl Lederis in 1980, the human homolog was identified in 1999 by Ames et al., who simultaneously identified its receptor as the orphan G protein-coupled receptor GPR14, now designated the UT receptor.

Overview

Urotensin II occupies a paradoxical position in cardiovascular biology. Despite being the most potent vasoconstrictor known, its effects in vivo are far more complex than simple vasoconstriction — UII produces vasodilation in some vascular beds while causing vasoconstriction in others, exhibits positive inotropic effects, promotes cardiac and vascular remodeling, and modulates metabolic function. This complexity has made UII both a fascinating research target and a challenging one for therapeutic development.

The UT receptor is widely distributed beyond the cardiovascular system, with expression in the central nervous system, kidneys, pancreas, adrenal glands, and skeletal muscle, suggesting broad physiological roles. In pathological states — particularly heart failure, pulmonary arterial hypertension, atherosclerosis, and metabolic syndrome — plasma UII levels and tissue UT receptor expression are significantly elevated, positioning the UII/UT system as both a biomarker and potential therapeutic target.

The clinical significance of UII has driven development of UT receptor antagonists, most notably palosuran (ACT-058362), which entered clinical trials for diabetic nephropathy, and SB-657510, which has been extensively characterized in preclinical models. While early clinical results with palosuran were disappointing, the evolving understanding of UII biology continues to reveal new potential therapeutic applications, particularly in pulmonary hypertension and cardiac fibrosis.

Mechanism of Action

Urotensin II exerts its effects through the UT receptor (formerly GPR14), a class A G protein-coupled receptor, via multiple intracellular signaling cascades:

UT Receptor Activation and Calcium Signaling: UII binding to the UT receptor activates Gq/11 proteins, stimulating phospholipase C-beta (PLCbeta) hydrolysis of PIP2 to IP3 and DAG. IP3 triggers calcium release from the sarcoplasmic reticulum, producing the sustained intracellular calcium elevation required for vascular smooth muscle contraction. This is amplified by Rho kinase (ROCK)-mediated calcium sensitization, which inhibits myosin light chain phosphatase, maintaining contractile tone even after calcium levels partially normalize.

Vasoconstriction: UII produces potent, sustained vasoconstriction in certain vascular beds — most notably pulmonary arteries, coronary arteries, and renal arteries — while causing vasodilation in others (mesenteric, cerebral). Vasoconstriction is mediated by direct smooth muscle UT receptor activation causing calcium mobilization and ROCK activation. The vasoconstrictive response is often characterized by sustained, "long-lasting" contraction with very slow washout, distinguishing it from other vasoactive peptides.

Vasodilation: In some vascular beds, UII produces endothelium-dependent vasodilation through UT receptor activation on endothelial cells, stimulating eNOS and NO release. This dual nature — constriction via smooth muscle UT receptors, dilation via endothelial UT receptors — explains the regional heterogeneity of UII vascular effects and is influenced by the balance of UT receptor expression between endothelium and smooth muscle.

Cardiac Inotropy: UII has positive inotropic effects on cardiomyocytes through UT receptor-mediated increases in intracellular calcium and PKC activation. However, chronic UII exposure promotes pathological cardiac hypertrophy through calcineurin/NFAT signaling and MAPK/ERK pathway activation, independent of hemodynamic loading.

Pro-Fibrotic Signaling: UII is a potent stimulator of fibroblast proliferation and collagen synthesis in cardiac, renal, and vascular tissues. This involves UT receptor-mediated activation of TGF-beta1/Smad signaling, connective tissue growth factor (CTGF) induction, and NADPH oxidase-dependent reactive oxygen species (ROS) generation. UII also promotes endothelin-1 expression, creating a pro-fibrotic feedforward loop.

Inflammatory Modulation: UII promotes vascular inflammation by stimulating expression of adhesion molecules (VCAM-1, ICAM-1) on endothelial cells, enhancing monocyte adhesion and transmigration. It activates NF-kB signaling and promotes expression of pro-inflammatory cytokines, contributing to atherosclerotic plaque formation and instability.

Research

Safety Profile

Urotensin II is not used therapeutically and its safety profile is characterized primarily through research administration and pathophysiological observation. Intravenous UII infusion in healthy volunteers produces dose-dependent cardiovascular effects including variable blood pressure changes (both increases and decreases depending on dose and vascular bed), increased cardiac output (positive inotropy), and flushing. At higher research doses, UII can cause coronary vasoconstriction, which is a significant safety concern. Bohm & Pernow (2002) demonstrated that UII causes potent vasoconstriction in human coronary arteries in vitro, raising concerns about potential ischemic effects. In patients with heart failure, exogenous UII may exacerbate hemodynamic compromise through coronary and renal vasoconstriction. The pro-fibrotic and pro-hypertrophic effects of chronic UII exposure contribute to progressive cardiac remodeling. UT receptor antagonists have demonstrated acceptable safety profiles in preclinical and early clinical studies, with primary concerns relating to potential hypotension and hemodynamic instability.

Clinical Research Protocols

• Research infusion (healthy volunteers): UII 5-50 pmol/kg/min IV infusion used to characterize hemodynamic effects in human studies.
• Research infusion (heart failure): Lower doses (1-20 pmol/kg/min) used with close hemodynamic monitoring due to heightened sensitivity in CHF patients.
• Forearm blood flow studies: Intra-arterial UII 0.5-50 pmol/min used to assess local vascular effects via venous occlusion plethysmography.
• Palosuran (UT antagonist): 125 mg oral twice daily tested in Phase II PROLONG trial for diabetic nephropathy (24 weeks).
• SB-657510 (UT antagonist): Extensively used preclinically; 30 mg/kg/day in rodent heart failure and PAH models.
• Key trials: PROLONG (palosuran in diabetic nephropathy, NCT00134108).
• Biomarker studies: Plasma UII measured by radioimmunoassay or ELISA in heart failure cohorts as prognostic marker.

Subpopulation Research

• Heart failure patients: Plasma UII levels are elevated 2-5 fold in CHF and correlate with NYHA class, NT-proBNP, and mortality risk (PMID: 12105159). UII may serve as an independent prognostic biomarker.
• Pulmonary hypertension patients: Elevated plasma UII and increased pulmonary artery UT receptor expression. UII levels correlate with pulmonary artery pressure, PVR, and right ventricular function (PMID: 22523266).
• Atherosclerosis patients: UII immunoreactivity is increased in coronary and carotid atherosclerotic plaques, particularly in macrophage-rich and unstable regions (PMID: 15072070).
• Diabetic nephropathy patients: Elevated plasma UII correlates with albuminuria, eGFR decline, and progression to end-stage renal disease (PMID: 15556850).
• Type 2 diabetes/metabolic syndrome: UII levels are elevated and correlate with insulin resistance, visceral adiposity, and dyslipidemia (PMID: 18316109).
• Essential hypertension: Inconsistent findings — some studies show elevated UII in hypertensives, others show no difference. The contribution of UII to essential hypertension may be vascular bed-specific.
• Preeclampsia: Elevated UII levels have been reported in preeclamptic pregnancies, potentially contributing to placental vasoconstriction and endothelial dysfunction.

Pharmacokinetic Profile

Ongoing & Future Research

• Next-generation UT antagonists: Development of more selective and potent UT receptor antagonists with improved pharmacokinetic profiles for oral administration. Biased UT receptor ligands that selectively block pro-fibrotic signaling while preserving beneficial endothelial effects are being explored.
• Pulmonary hypertension trials: UT antagonism is considered one of the most promising clinical applications, with preclinical data supporting efficacy comparable to established PAH therapies (bosentan, sildenafil). Clinical trials are anticipated.
• Cardiac fibrosis: UII as a direct target for anti-fibrotic therapy in heart failure with preserved ejection fraction (HFpEF), where myocardial fibrosis is a dominant pathological feature and current therapies are limited.
• UII as biomarker: Validation of plasma UII as a prognostic biomarker for heart failure outcomes, PAH severity, and acute coronary syndrome risk stratification. Multi-center prospective studies are ongoing.
• Cancer biology: Emerging evidence of UII/UT expression in colorectal, hepatocellular, and adrenocortical carcinomas, with potential roles in tumor angiogenesis and growth. UT antagonism has shown anti-tumor effects in preclinical cancer models.
• Structural biology: Cryo-EM and X-ray crystallography studies of the UT receptor in complex with UII and antagonists are advancing structure-based drug design for next-generation therapeutics.
• URP biology: Distinguishing the specific roles of UII versus URP at the UT receptor — these co-ligands may have distinct signaling bias and tissue-specific functions that could be therapeutically exploited.